Apellis Pharmaceuticals, Inc.(APLS)Earnings, Financials & Key RatiosApellis Pharmaceuticals, Inc. (APLS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a healthy 3.63 current ratio, the extreme volatility in quarterly earnings and the negative 3.27 OCF/NI ratio in 2026Q1 warrant a cautious wait-and-see approach until commercial adoption stabilizes.
Apellis Pharmaceuticals, Inc. (APLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Apellis Pharmaceuticals, Inc. (APLS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.15vs $0.38+139.5% | $268Mvs $210M+27.5% |
| Q1 2026 | Feb 24, 2026 | $0.47vs $0.39-20.5% | $200Mvs $199M+0.3% |
| Q4 2025 | Oct 30, 2025 | $1.67vs $1.03+62.1% | $459Mvs $199M+130.1% |
| Q3 2025 | Jul 31, 2025 | $0.33vs $0.44+25.0% | $178Mvs $372M-52.0% |
Recent stock market news and headlines for Apellis Pharmaceuticals, Inc. (APLS)
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6 billion earlier this year.
Key metrics vs top competitors for Apellis Pharmaceuticals, Inc. (APLS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $41.03 | $5.25B | 227.94 | 28.46% | 2.23% | 7.48% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $54.65 | $4.5B | -14.57 | — | — | -30.58% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $4.08 | $5.15M | -0.08 | -81.82% | -2530.85% | — | — |
Apellis Pharmaceuticals, Inc. (APLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Apellis Pharmaceuticals, Inc. (APLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 4, 2026·SEC
Mar 31, 2026·SEC
Mar 2, 2026·SEC
Get notified when APLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Apellis Pharmaceuticals, Inc. (APLS) stock FAQ — growth, dividends, profitability & financials explained
Apellis Pharmaceuticals, Inc. (APLS) reported $1.03B in revenue for fiscal year 2025.
Apellis Pharmaceuticals, Inc. (APLS) grew revenue by 28.5% over the past year. This is strong growth.
Yes, Apellis Pharmaceuticals, Inc. (APLS) is profitable, generating $133.3M in net income for fiscal year 2025 (2.2% net margin).
Apellis Pharmaceuticals, Inc. (APLS) has a return on equity (ROE) of 7.5%. This is below average, suggesting room for improvement.
Apellis Pharmaceuticals, Inc. (APLS) generated $37.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
